Skip to main content

Advertisement

SpringerLink
Log in

Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Systemic hypertension is common in patients with acute as well as with chronic renal diseases. Hypertension is an important factor that contributes to the progression of renal failure. Cardiovascular disease is the leading cause of death and disability in patients with chronic renal failure and in those receiving renal replacement therapy. The prevalence of hypertensive nephropathy remains unabated. Hypertension and chronic renal failure are closely interlinked and govern the morbidity and mortality in patients afflicted by these conditions. There is considerable hope that effective control of hypertension may retard the progression of renal disease. Although mere control of hypertension is of paramount importance, specific pharmacologic approaches may offer certain important renal advantages. Angiotensin-converting enzyme (ACE) inhibitors, by the virtue of their intrarenal effects, exert favorable consequences on the kidney function (and structure, to some extent), particulary in patients with diabetic nephropathy and hypertension. Both experimental and clinical studies have demonstrated the renoprotective effects of ACE inhibitors; these drugs slow down the progression of renal disease independent of their antihypertensive actions. More recently, angiotensin-receptor blockers have been shown to exert similar glomerular effects as ACE inhibitors. Preliminary clinical data also suggest a possible role for angiotensinreceptor blockers in the prevention of progression of renal failure. Therapeutic agents that inhibit the reninangiotensin axis hold considerable promise in the management of patients with renal disease by slowing down the rate of decline in renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. US Renal Data Systems: USRDS 1997 Annual Data Report: V. Patient mortality and survival. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease. Am J Kidney Dis 1997, 30(suppl 1):S86-S106. This is a comprehensive report on the prevalence of and outlook for patients with chronic renal disease in the United States. The report unravels mortality and survival data for patients with ESRD. Attributes characterizing the prognosis of patients with ESRD are discussed in this article.

    Google Scholar 

  2. Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic and cardiovascular risks: U.S. Population Data. Arch Intern Med 1993, 153:598–615. This review illustrates the prognostic significance of diastolic as well as systolic blood pressure in American adults. The authors provide convincing evidence to illustrate the linear relationship between the blood pressure level and morbidity/mortality. The risks of high blood pressure are clearly and succinctly revealed in this article.

    Article  PubMed  CAS  Google Scholar 

  3. Tomita J, Kimura G, Inoue T, et al.: Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995, 25:405–412.

    PubMed  CAS  Google Scholar 

  4. DeGoulet P, Legrain M, Reach I, et al.: Mortality risk factors in patients treated with chronic hemodialysis. Nephron 1982, 31:103–110. This article defines the spectrum of cardiovascular risk factors that contribute to the mortality in patients with ESRD. The study identifies the impact of high blood pressure on the survival of patients undergoing hemodialysis.

    PubMed  CAS  Google Scholar 

  5. Fernandez JM, Carbonnel ME, Mazzuchi N: Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients. Kidney Int 1992, 41:1029–1034.

    PubMed  CAS  Google Scholar 

  6. Cannella G, Pauletti E, Delfino R, et al.: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993, 44:881–886. This paper demonstrates the development of left ventricular hypertrophy (LVH) as a surrogate result of hypertension in patients with chronic renal failure. Importantly, the study shows that with sustained antihypertensive therapy, it is possible to reverse LVH, which is a desirable therapeutic goal in the management of hypertension.

    PubMed  CAS  Google Scholar 

  7. Harnett JD, Kent GM, Barre PE, et al.: Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994, 4:1486–1490.

    PubMed  CAS  Google Scholar 

  8. Ritz E, Strympf C, Katz F, et al.: Hypertension and cardiovascular factors in hemodialyzed diabetic patients. Hypertension 1985, 7:118–124. This article reviews the inter-relationship of cardiovascular risk factors in diabetic patients with ESRD. The study also underscores the critical importance of hypertension in diabetic nephropathy; therapeutic implications are discussed.

    Google Scholar 

  9. Tozawa M, Iseki K, Fukiyama K: Hypertension in dialysis patients: a cross-sectional analysis. Jpn J Nephrol 1997, 3:129–135.

    Google Scholar 

  10. Ang KS, Simon P, Cam G: Ambulatory blood pressure during the interdialytic period in uremic patients treated by hemodialysis. Kidney Int 1989, 35:238.

    Google Scholar 

  11. Cheigh JS, Milite C, Sullivan JF, et al.: Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 1992, 19:453–459. This study reveals that blood pressure is poorly controlled in hemodialysis patients. There might be multiple mechanisms responsible for inadequate control of hypertension in the ESRD patients. This paper reaffirms the urgent need to manage hypertension more effectively and aggressively in patients with ESRD.

    PubMed  CAS  Google Scholar 

  12. Salem MM: Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995, 26:461–468.

    PubMed  CAS  Google Scholar 

  13. Laffel LM, McGill JB, Gans DJ: The beneficial effects of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497–503.

    Article  PubMed  CAS  Google Scholar 

  14. Viberti G, Morgensen CE, Groop LC, Pauls JF: Effect of captopril on clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria captopril Study Group. JAMA 1994, 271:275–279.

    Article  PubMed  CAS  Google Scholar 

  15. Lewis JE, Hunsicker LG, Baine RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462. This prospective, randomized clinical trial shows that long-term ACE inhibitor therapy in subjects with diabetic nephropathy is not only safe but prolongs the predialytic interval and arrests the progression of renal disease.

    Article  PubMed  CAS  Google Scholar 

  16. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin converting enzyme benazepril in progression of chronic renal insufficiency. N Engl J Med 1996, 334:939–945.

    Article  PubMed  CAS  Google Scholar 

  17. Giatras I, Lau J, Levey AS, for the ACE inhibition and progressive renal disease study group: Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997, 127:337–345. This paper offers a broad meta-analysis of well-done clinical trials using ACE inhibition therapy for renal protection; in this review, the authors discuss the similarities and differences among the studies analyzed. The overall comprehensive analysis points to the potential benefit of ACE inhibitors to retard the progression of renal disease.

    PubMed  CAS  Google Scholar 

  18. Ruggeneti P, Remuzzi G: Angiotensin converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997, 6:489–494.

    Article  Google Scholar 

  19. Hollenberg NK: Pharmacologic interruption of the reninangiotensin system and the kidney: differential responses to angiotensin converting enzyme and renin inhibition. J Am Soc Nephrol 1999, 10:S239-S242.

    PubMed  CAS  Google Scholar 

  20. Hollenberg NK, Raij L: Angiotensin-converting enzyme inhibition and renal protection: an assessment of implications for therapy. Arch Intern Med 1993, 153:2426–2435.

    Article  PubMed  CAS  Google Scholar 

  21. Bayer JM: Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? Curr Opin Nephrol Hypertens 1995, 4:427–431.

    Article  Google Scholar 

  22. Keilani T, Danesh F, Schlueter WA, et al.: A supdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999, 33:450–457. This clinical study proves that the antiproteinuric effects of ACE inhibitors occur at doses that do not produce a fall in systemic blood pressure. ACE inhibitors can influence the glomerular dynamics independent of their systemic hemodynamic effects. This finding may have a clinical bearing on the application of ACE inhibitors in those patients with diabetic nephropathy who have normal or low blood pressure.

    PubMed  CAS  Google Scholar 

  23. Kon V, Fogo A, Ichikawa I, et al.: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993, 44:545–550.

    PubMed  CAS  Google Scholar 

  24. Komers R, Cooper ME: Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995, 37:F58-F594. This paper demonstrates the role of intrarenal bradykinin system in regulating the glomerular filtration characteristics; the effects of ACE inhibition on the kidney may be modulated by bradykinin. If this is the case, ACE inhibitors, not the angiotensin receptor blockers (ARBs) may be beneficial to correct the glomerular hyperfiltration in diabetes.

    Google Scholar 

  25. Veelken R, Hilgers KF, Setter A, et al.: Nerve mediated antidiuresis and anti-natriuresis after air-jet stress is modulated by angiotensin II. Hypertension 1996, 28:825–832.

    PubMed  CAS  Google Scholar 

  26. Burnier M, Rutschmann B, Nussberger J: Salt dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993, 22:339–347.

    PubMed  CAS  Google Scholar 

  27. Gansevoort RT, deZeeuw D, deJong PE: Is the antiproteinuric effect of ACE inhibitors mediated by interference in the renin-angiotensin system? Kidney Int 1994, 45:861–867. This study demonstrates that a reduction in proteinuria can be obtained by blocking the angiotensin II receptors. ARBs and ACE inhibitors produce a comparable antiproteinuric effect. ARBs (like ACE inhibitors) may exert a renoprotective effect independent of their blood pressure lowering effect.

    PubMed  CAS  Google Scholar 

  28. Plum J, Bunten B, Nemeth R, Grabenesee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998, 9:2223–2234. This clinical study shows that ARBs have a favorable effect on renal hemodynamics and glomerular function in patients with chronic renal failure. The findings of this trial should pave the way for larger controlled clinical trials to further evaluate the definite role of ARBs in arresting the progression of renal disease.

    PubMed  CAS  Google Scholar 

  29. Lafayette RA, Mayer G, Park SK, Meyer TK: Angiotensin II receptor blockade limits glomerular injury in rats with induced renal mass. J Clin Invest 1992, 90:766–771.

    Article  PubMed  CAS  Google Scholar 

  30. Remuzzi A, Perico N, Amuchastegnui CS: Short and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993, 4:40–49.

    PubMed  CAS  Google Scholar 

  31. Toto R, Shultz P, Raij L, et al.: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998, 31:684–691.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Texas Blood Pressure Institute at Dallas Nephrology Associates and University of Texas Southwestern Medical Center, 6010 Forest Park Road, 75235, Dallas, Texas, USA

    C. Venkata S. Ram MD & Pedro Vergne-Marini MD

Authors
  1. C. Venkata S. Ram MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro Vergne-Marini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ram, C.V.S., Vergne-Marini, P. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease. Current Science Inc 1, 431–435 (1999). https://doi.org/10.1007/s11906-999-0060-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0060-3

Keywords

Search

Navigation